Exploring a new treatment for systemic lupus erythematosus using bacterial DNA
CpG-B ODN Mediated Protection from Systemic Lupus Erythematosus
This study is looking at a new treatment for lupus that uses tiny pieces of bacterial DNA to help your immune system work better and reduce side effects from current medications.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Polytechnic Inst and St Univ NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project ID | NIH-10998519 on NIH RePORTER |
What this research studies
This research investigates a potential new therapy for systemic lupus erythematosus (SLE), a chronic autoimmune disease. The approach focuses on the gut microbiome's role in immune regulation, specifically using bacterial DNA to stimulate the production of beneficial immune cells. By utilizing short sequences of DNA that mimic bacterial DNA, the study aims to enhance the body's immune response while minimizing the side effects associated with current treatments. The research will explore how these sequences can promote the proliferation of regulatory B cells, which may lead to improved management of lupus symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus who are seeking new treatment options.
Not a fit: Patients with other autoimmune diseases or those not diagnosed with systemic lupus erythematosus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with systemic lupus erythematosus, potentially reducing reliance on corticosteroids and immunosuppressants.
How similar studies have performed: Other research has shown promise in using bacterial DNA to modulate immune responses, indicating that this approach may lead to significant advancements in lupus treatment.
Where this research is happening
Blacksburg, United States
- Virginia Polytechnic Inst and St Univ — Blacksburg, United States (Active)
Researchers
- Principal investigator: Oakland, David Noah — Virginia Polytechnic Inst and St Univ
- Study coordinator: Oakland, David Noah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.